Catherine P. Cortés Vesga

Catherine P. Cortés Vesga

Auto-generated profile, based on publicly available information

Catherine P. Cortés Vesga

Medical Systems Biology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universit€ at Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their dependence on mutant KRAS. However, analysis of the remaining cell population after long-term Cas9 expression unmasked the occurence of oncogenic KRAS escape variants that were resistant to Cas9-cleavage. In contrast, the use of an adenine base editor to correct oncogenic KRAS mutations progressively depleted the targeted cells without the appearance of escape variants and allowed efficient and simultaneous correction of a cancer-associated TP53 mutation. Oncogenic KRAS and TP53 base editing was possible in patient-derived cancer organoids, suggesting that base editor approaches to correct oncogenic mutations could be developed for functional interrogation of vulnerabilities in a personalized manner for future precision oncology applications. Significance: Repairing KRAS mutations with base editors can be used for providing a better understanding of RAS biology and may lay the foundation for improved treatments for KRAS-mutant cancers.

31 March 2023
Verified
Other
Open access
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
Supplementary Data from Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

31 March 2023
Verified
Other
Open access
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
Supplementary Data from Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

31 March 2023
Verified
Other
Open access
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz

31 March 2023
Verified
Other
Open access
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
Supplementary Data from Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

31 March 2023
Verified
Other
Open access
SSShady Sayed
Shady Sayed
OSOlga A. Sidorova
Olga A. Sidorova
AHAlexander Hennig
Alexander Hennig
MAMartina Augsburg
Martina Augsburg
CVCatherine P. Cortés Vesga
Catherine P. Cortés Vesga
FBFrank Buchholz
Frank Buchholz
Supplementary Data from Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing